These were the best performers on the FTSE 100 in January

The FTSE 100 might have got off to a slow start this year, but these top-performing stocks certainly didn’t. Why have they been marching higher?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

British flag, Big Ben, Houses of Parliament and British flag composition

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 started the year with a whimper. It dropped 1.33% in January to finish at 7,630 points. For context, it was at 7,730 in January 2018.

Fortunately, investors can choose to pick individual Footsie shares rather than worry about the wider index. And those holding these four FTSE 100 shares will have been satisfying last month.

Flutter Entertainment

Flutter Entertainment (LSE: FLTR) has decided to spread its wings and fly across the pond. It listed in the US on 29 January and intends to switch its primary listing from London to New York “as soon as practicable”.

The firm said the move will make the stock “more accessible to US-based investors and gain access to deeper capital markets.”

In essence, it wants a higher valuation and thinks New York will provide that. This arguably became self-fulfilling as the stock surged 16.8% last month.

The move makes sense as Flutter, which owns Paddy Power and BetFair, is one of the world’s largest gambling companies. And right now there’s a boom in US online sports betting, which was illegal until 2018. The firm also owns FanDuel, a US leader in this area.

Last year, the firm generated revenue of £9.5bn, a third of which came from North America. Future regulation is a threat, but it appears to have huge growth prospects if all US states legalise sports betting (not all have).

GSK

Next, we have pharma giant GSK. The stock jumped an impressive 8.1% last month as investors cheered its new RSV vaccine Arexvy achieving blockbuster status.

That is, the drug brought in more than $1bn in sales last year. That’s remarkable considering it was only out for roughly six months.

Litigation related to its discontinued heartburn drug Zantac continues to hang over the stock, though. Consequently, it’s dirt cheap on a price-to-earnings (P/E) ratio of 10.

Hikma Pharmaceuticals

Third, we have Hikma Pharmaceuticals (LSE: HIK). Shares of the generics and injectables manufacturer progressed 7.9% in January.

In November, it upgraded its full-year guidance in two of its three divisions. Then, in January, a deal was announced with US liquid biopsy firm Guardant Health.

This was to promote the latter’s next-generation sequencing tests for cancer screening, recurrence monitoring and tumour mutation profiling for solid cancers in the Middle East and North Africa. Hikma has a good presence across those markets.

The company faces regulatory risks as a pharmaceutical firm, but investors may have been drawn to the stock’s very undemanding forward P/E ratio of 11.5.

BAE Systems

Finally, we have BAE Systems (LSE: BA.), whose inclusion is no mystery. Iran-backed Houthi rebels are causing chaos in the Red Sea and and three US troops were recently killed in a drone strike in Jordan. This is threatening to spill over into a much wider Middle East conflict.

In response, the BAE share price has now risen 5.9% this year. And it has almost doubled since Russian’s invasion of Ukraine nearly two years ago.

One thing I’d highlight here is valuation. Prior to the Russia-Ukraine conflict, the stock’s P/E ratio was around 10.5 (or 76%) less than the 18.5 it is today.

That said, geopolitics hasn’t been this unstable for many decades, which is reflected in the defence giant’s record order backlog of £66.2bn.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in BAE Systems. The Motley Fool UK has recommended BAE Systems, GSK, Guardant Health, and Hikma Pharmaceuticals Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 tried and tested ways to earn passive income in 2025

Our writer examines the latest market trends and economic forecasts to uncover three great ways to earn passive income in…

Read more »

Investing Articles

Here’s what £10k invested in the FTSE 100 at the start of 2024 would be worth today

Last week's dip gives the wrong impression of the FTSE 100, which has had a pretty solid year once dividends…

Read more »

Investing Articles

UK REITs: a once-in-a-decade passive income opportunity?

As dividend yields hit 10-year highs, Stephen Wright thinks real estate investment trusts could be a great place to consider…

Read more »

Investing Articles

Is Helium One an amazing penny stock bargain for 2025?

Our writer considers whether to invest in a penny stock that’s recently discovered gas and is now seeking to commercialise…

Read more »

Investing Articles

Here are the 10 BIGGEST investments in Warren Buffett’s portfolio

Almost 90% of Warren Buffett's Berkshire Hathaway portfolio is invested in just 10 stocks. Zaven Boyrazian explores his highest-conviction ideas.

Read more »

Investing Articles

Here’s the stunning BP share price forecast for 2025

The BP share price enters 2025 in poor shape, after a tricky year for energy stocks. Harvey Jones looks at…

Read more »

Investing Articles

How to target a £100,000 second income starting with just £1,000

Zaven Boyrazian explains the various strategies investors can use to try and earn a £100,000 second income in the stock…

Read more »

Investing Articles

My 5 BIGGEST Stocks and Shares ISA investments for 2025 and beyond

Zaven Boyrazian shares his largest Stocks and Shares ISA investments made this year. Each has explosive growth potential, but they…

Read more »